Evidence map›Paper›PMID 41062491›Full record

ArticleScientific reports2025

Assessing the risk of recurrence in early-stage breast cancer through H&E stained whole slide images.

Geongyu Lee, Joonho Lee, Tae-Yeong Kwak, Sun Woo Kim, Youngmee Kwon, Chungyeul Kim, Hyeyoon Chang

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Geongyu LeeResearch Team, Deep Bio Inc., Seoul, Seoul, 08380, Republic of Korea.
Joonho LeeResearch Team, Deep Bio Inc., Seoul, Seoul, 08380, Republic of Korea.
Tae-Yeong KwakResearch Team, Deep Bio Inc., Seoul, Seoul, 08380, Republic of Korea.
Sun Woo KimResearch Team, Deep Bio Inc., Seoul, Seoul, 08380, Republic of Korea.
Youngmee KwonDepartment of Pathology, National Cancer Center, Goyang, Goyang, 10408, Republic of Korea.
Chungyeul KimDepartment of Pathology, Korea University Guro Hospital, Seoul, Seoul, 08380, Republic of Korea. idea1@korea.ac.kr.
Hyeyoon ChangDepartment of Pathology, Deep Bio Inc., Seoul, Seoul, 08380, Republic of Korea. hychang@deepbio.co.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate prediction of the likelihood of recurrence is important in the selection of postoperative treatment for patients with early-stage breast cancer. In this study, we investigated whether deep learning algorithms can predict patients' risk of recurrence by analyzing the pathology images of their cancer histology. We analyzed 125 hematoxylin and eosin-stained whole slide images (WSIs) from 125 patients across two institutions (National Cancer Center and Korea University Medical Center Guro Hospital) to predict breast cancer recurrence risk using deep learning. Sensitivity reached 0.857, 0.746, and 0.529 for low, intermediate, and high-risk categories, respectively, with specificity of 0.816, 0.803, and 0.972, and a Pearson correlation of 0.61 with histological grade. Class activation maps highlighted features like tubule formation and mitotic rate, suggesting a cost-effective approach to risk stratification, pending broader validation. These findings suggest that deep learning models trained exclusively on hematoxylin and eosin stained whole slide images can approximate genomic assay results, offering a cost-effective and scalable tool for breast cancer recurrence risk assessment. However, further validation using larger and more balanced datasets is needed to confirm the clinical applicability of our approach.

Indexed as

Breast NeoplasmsNeoplasm Recurrence, LocalAdultAgedDeep LearningEosine Yellowish-(YS)FemaleHematoxylinHumansMiddle AgedNeoplasm StagingRisk AssessmentStaining and LabelingEosine Yellowish-(YS)HematoxylinBreast cancerDeep learningOncotypeDXRecurrence risk

Identifiers

PMID41062491
PMCPMC12508429

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.